<code id='00127FA9FF'></code><style id='00127FA9FF'></style>
    • <acronym id='00127FA9FF'></acronym>
      <center id='00127FA9FF'><center id='00127FA9FF'><tfoot id='00127FA9FF'></tfoot></center><abbr id='00127FA9FF'><dir id='00127FA9FF'><tfoot id='00127FA9FF'></tfoot><noframes id='00127FA9FF'>

    • <optgroup id='00127FA9FF'><strike id='00127FA9FF'><sup id='00127FA9FF'></sup></strike><code id='00127FA9FF'></code></optgroup>
        1. <b id='00127FA9FF'><label id='00127FA9FF'><select id='00127FA9FF'><dt id='00127FA9FF'><span id='00127FA9FF'></span></dt></select></label></b><u id='00127FA9FF'></u>
          <i id='00127FA9FF'><strike id='00127FA9FF'><tt id='00127FA9FF'><pre id='00127FA9FF'></pre></tt></strike></i>

          00:00
          00:00 00:00 LIVE
          buffering
          Replay
          LIVE
          00:00 / 00:00
          LIVE
          CC
          Opacity :
          Share:
          Close

          leisure time

          author:hotspot    - browse:7259
          Adam's take main illustration
          Molly Ferguson/STAT

          Biotech is awash in PIPEs.

          The numbers behind these privately negotiated purchases of public-company stock are astounding. By my count, there have been 30 PIPE transactions involving public biotechs and institutional investors (mostly hedge funds) that have raised $4 billion in the first two months of the year.

          advertisement

          Just this week, five biotechs have brought in a combined $950 million via PIPEs, including Denali Therapeutics raising $500 million, the largest such financing this year. Crinetics Pharmaceuticals raised $350 million.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          entertainment